BackgroundCheck.run
Search For

Henry J Mcfarland, 812652 Horton Hill Rd, Herndon, VA 20171

Known as:
Holly Mcfarland Harry Mcfarland Melissa Smith
Related to:
John S Mccormick 54 Man Ho Fisher 69

Henry Mcfarland Phones & Addresses

2652 Horton Hill Rd, Herndon, VA 20171    703-3919470    703-3919479   

Leander, TX   

Essex, MD   

Glendale, AZ   

Kingsville, MD   

Get Report
Control this profile

Mentions for Henry J Mcfarland

Career records & work history

Medicine Doctors

Henry Mcfarland Photo 1

Henry Fruth McFarland, Bethesda MD

Specialties:
Neurology
Psychiatry
Surgery
Work:
National Institutes Of Health
9000 Rockville Pike, Bethesda, MD 20892
Education:
University of Colorado (1966)

License Records

Henry Joseph Mcfarland

Licenses:
License #: 72807 - Expired
Category: Nursing Support
Issued Date: Jul 31, 2012
Effective Date: Aug 12, 2014
Expiration Date: Jul 31, 2014
Type: Medication Aide

Henry Joseph Mcfarland

Licenses:
License #: 978536 - Expired
Category: Swimming Pool Operator
Issued Date: May 22, 2007
Effective Date: Mar 24, 2010
Expiration Date: May 22, 2009
Type: Swimming Pool Operator

Henry Fruth Mcfarland

Address:
Towson, MD 21204
Licenses:
License #: MD009882E - Expired
Category: Medicine
Type: Medical Physician and Surgeon

Henry Mcfarland resumes & CV records

Resumes

Henry Mcfarland Photo 19

Henry Mcfarland

Henry Mcfarland Photo 20

Henry Mcfarland

Henry Mcfarland Photo 21

Henry Mcfarland

Publications & IP owners

Us Patents

Method For The Treatment Of Multiple Sclerosis

US Patent:
7258859, Aug 21, 2007
Filed:
Jun 27, 2003
Appl. No.:
10/607598
Inventors:
Roland Martin - Bethesda MD, US
Henry McFarland - Gaithersburg MD, US
Bibiana Bielekova - Kensington MD, US
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC
International Classification:
A61K 39/00
A61K 38/21
US Classification:
4241841, 424 856, 4241431
Abstract:
A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of an IL-21 receptor antagonist, wherein the subject has failed to respond treatment with beta interferon, thereby treating the subject.

Method Of Treating Autoimmune Diseases With Interferon-Beta And Il-2R Antagonist

US Patent:
7575742, Aug 18, 2009
Filed:
Nov 27, 2002
Appl. No.:
10/519311
Inventors:
Roland Martin - Bethesda MD, US
Henry McFarland - Gaithersburg MD, US
Bibiana Bielekova - Kensington MD, US
Thomas Waldmann - Silver Spring MD, US
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC
International Classification:
A61K 38/21
A61K 39/395
C07K 14/00
C07K 16/00
US Classification:
424 854, 4241431, 530351, 53038822
Abstract:
Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments the autoimmune disease is multiple sclerosis. In certain embodiments administration of interferon-beta is combined with administration of an antagonist of the IL-2R to provide significant clinical improvement in a subject with an autoimmune disease.

Quinone Derivative 2,3-Dimethoxy-5-Methyl-6-(10-Hydroxydecyl)-1,4-Benzoquinone For The Treatment Of Primary Progressive Multiple Sclerosis

US Patent:
8293800, Oct 23, 2012
Filed:
Apr 28, 2010
Appl. No.:
12/768930
Inventors:
Thomas Meier - Basel, CH
Bibiana Bielekova - Kensington MD, US
Henry F. McFarland - Gaithersburg MD, US
Assignee:
Santhera Pharmaceuticals (Schweiz) AG - Liestal
The United States of America, as represented by the Secretary, Department of Health and Human Services - Washington DC
International Classification:
A61K 31/12
US Classification:
514689, 514678
Abstract:
The present invention relates to approaches, methods, pharmaceuticals and uses directed to the curative treating or preventing of Primary Progressive Multiple Sclerosis (PP-MS), by using 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (Idebenone) as the active agent.

Method Of Treating Multiple Sclerosis With Interferon-Beta And An Il-2R Antagonist

US Patent:
8298525, Oct 30, 2012
Filed:
Mar 10, 2009
Appl. No.:
12/401543
Inventors:
Roland Martin - Bethesda MD, US
Henry McFarland - Gaithersburg MD, US
Bibiana Bielekova - Kensington MD, US
Thomas Waldmann - Silver Spring MD, US
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC
International Classification:
A61K 38/21
A61K 39/395
A61K 38/20
C07K 14/55
C07K 16/28
US Classification:
424 854, 4241431, 530351, 5303882
Abstract:
Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments the autoimmune disease is multiple sclerosis. In certain embodiments administration of interferon-beta is combined with administration of an antagonist of the IL-2R to provide significant clinical improvement in a subject with an autoimmune disease.

Method For The Treatment Of Multiple Sclerosis

US Patent:
8454965, Jun 4, 2013
Filed:
Jul 13, 2007
Appl. No.:
11/827876
Inventors:
Roland Martin - Hamburg, DE
Henry McFarland - Gaithersburg MD, US
Bibiana Bielekova - Kensington MD, US
Assignee:
The United States of America as represented by The Secretary of the Department of Health and Human Services - Washington DC
International Classification:
A61K 39/00
A61K 39/395
C07K 16/00
US Classification:
4241841, 4241431, 5303881, 53038822
Abstract:
A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of an IL-21 receptor antagonist, wherein the subject has failed to respond treatment with beta interferon, thereby treating the subject.

Method Of Treating Multiple Sclerosis With Interferon-Beta And An Il-2R Antagonist

US Patent:
8636997, Jan 28, 2014
Filed:
Sep 12, 2012
Appl. No.:
13/612763
Inventors:
Roland Martin - Bethesda MD, US
Henry McFarland - Gaithersburg MD, US
Bibiana Bielekova - Kensington MD, US
Thomas Waldmann - Silver Spring MD, US
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC
International Classification:
A61K 38/21
A61K 39/395
C07K 14/565
C07K 16/28
US Classification:
424 856, 4241441, 530351, 53038822
Abstract:
Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments the autoimmune disease is multiple sclerosis. In certain embodiments administration of interferon-beta is combined with administration of an antagonist of the IL-2R to provide significant clinical improvement in a subject with an autoimmune disease.

Methods For Selection Of Subjects For Multiple Sclerosis Therapy

US Patent:
2007023, Oct 11, 2007
Filed:
Apr 5, 2004
Appl. No.:
11/578207
Inventors:
Roland Martin - Bethesda MD, US
Louis Staudt - Silver Spring MD, US
Henry McFarland - Gaithersburg MD, US
Claus-Steffen Sturzebecher - Berlin, DE
International Classification:
A61K 49/00
C12Q 1/68
US Classification:
424009100, 435006000
Abstract:
A variety of therapies are used to treat autoimmune diseases such as multiple sclerosis. However, there is no single therapy that can be used to treat all subjects. Thus, a method is provided to determine if a subject with an autoimmune disease, such as multiple sclerosis, will respond to a therapeutic protocol. The method includes analyzing the expression of genes expressed by the immune system. Although the expression of a single gene can be assessed, such as interleukin-8, the methods include evaluating the expression profile of a subject using an array (such as a microarray) to determine if the subject is appropriately responding to the therapeutic protocol.

Method For The Treatment Of Multiple Sclerosis

US Patent:
2013001, Jan 17, 2013
Filed:
May 18, 2012
Appl. No.:
13/475688
Inventors:
Roland MARTIN - Bethesda MD, US
Henry McFarland - Gaithersburg MD, US
Bibiana Bielekova - Kensington, MD, US
International Classification:
A61K 39/395
A61P 25/00
A61K 49/06
US Classification:
424 93, 4241721, 4241331
Abstract:
A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of an IL-21 receptor antagonist, wherein the subject has failed to respond treatment with beta interferon, thereby treating the subject.

Possible Relatives

Cynthia N Mcfarland  David W Mcfarland  Dawn Mcfarland  Dean A Mcfarland  Deanna A Mcfarland  Dale R Mcfarland  Dallas E Mcfarland  Henry Johnson  Henry A Stamschror  Henry A Stanaland 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.